Omnicell Reports $307.9 Million in Q3 Revenue
Healthcare operators should track these results to gauge shifting capital expenditure trends in medical automation.
Updated on Oct. 29, 2026 in Economic Indicators
Live Poll
Do you generally trust corporate earnings reports that exceed Wall Street analyst expectations?
Fort Worth-based Omnicell reported third-quarter 2026 earnings of $11 million on $307.9 million in revenue. The medical technology firm also issued financial guidance for the remainder of the fiscal year.
Why it matters
For operators, Omnicell’s performance offers a signal on the financial health of the healthcare automation sector. These results indicate current demand levels as the company sets expectations for the fourth quarter.
Omnicell recorded $307.9 million in revenue for the third quarter of 2026. The company currently projects full-year revenue of $1.23 billion with earnings per share ranging from $2.48 to $2.56.
The players
Omnicell
A Fort Worth-based provider of pharmacy automation and medication management technology for healthcare facilities.
The details
Omnicell reports its financial results through standard profit metrics and adjusted earnings, which account for non-recurring or non-cash charges. Management’s forward-looking guidance provides a benchmark for the sector, with the company anticipating fourth-quarter revenue between $295 million and $301 million. These figures help suppliers and partners gauge the scale of activity within the medical automation market.
Timeline
Omnicell reported $11 million in earnings for Q3 2026.
The fiscal fourth quarter ends in December 2026.
Market Landscape
Omnicell's revenue performance reflects broader trends in healthcare infrastructure investment influenced by the CMS hospital price transparency rule. The company continues to compete in a market where hospitals increasingly prioritize automated medication management to drive operational efficiencies.
Operators should monitor Omnicell’s fourth-quarter revenue guidance of $295 million to $301 million as a proxy for hospital capital expenditure budgets. Watching these figures helps gauge the pace of technology adoption and consolidation in medical supply chains.
The takeaway
The firm’s performance highlights the ongoing importance of tracking automation adoption in clinical settings to predict regional healthcare spending shifts. Monitor the company’s December year-end filings for final 2026 revenue performance against the current $1.23 billion target.
What happens next
Omnicell will conclude its fiscal year at the end of December 2026, which will provide final data on whether the firm met its $1.23 billion annual revenue target.
Further reading
For broader trends in regional business performance, visit Economic Indicators.
Source note: This article includes information reported by WTOP.
Live Poll
Do you generally trust corporate earnings reports that exceed Wall Street analyst expectations?
